SCHEMBL30748845

SCHEMBL30748845

C=Cc1ncc2ccn(-c3ccc(Oc4ccccc4)cc3)c2n1

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PTK2 Q05397 4/20 0.38
RPS6KA3 P51812 3/20 0.38
AURKA O14965 3/20 0.38
DAPK3 O43293 2/20 0.38
JAK2 O60674 2/20 0.38
PAK4 O96013 2/20 0.38
NTRK1 P04629 2/20 0.38
LCK P06239 2/20 0.38
FYN P06241 2/20 0.38
CSF1R P07333 2/20 0.38
RET P07949 2/20 0.38
IGF1R P08069 2/20 0.38
FGFR1 P11362 2/20 0.38
PRKACA P17612 2/20 0.38
KDR P35968 2/20 0.38
MAPK8 P45983 2/20 0.38
MAPK9 P45984 2/20 0.38
CLK2 P49760 2/20 0.38
JAK3 P52333 2/20 0.38
TYRO3 Q06418 2/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30749046 0.87 RPS6KA3 (0.38) PTK2RPS6KA3AURKADAPK3JAK2
SCHEMBL30748920 0.77 LTA4H (0.40) PTK2RPS6KA3AURKADAPK3JAK2
SCHEMBL30748788 0.67 MGLL (0.40) MGLLALDH1A1SMN1; SMN2POLBUSP2
SCHEMBL12069031 0.67 BIRC5 (0.61) NTRK1IGF1RFGFR1PRKACANTRK2
SCHEMBL11916210 0.65 JAK2 (0.44) PTK2RPS6KA3AURKADAPK3JAK2
SCHEMBL26270373 0.65 MAPKAPK2 (0.56) RPS6KA3AURKADAPK3JAK2PAK4
SCHEMBL29650985 0.65 JAK2 (0.44) PTK2RPS6KA3AURKADAPK3JAK2
SCHEMBL17464105 0.64 SRC (0.39) PTK2RPS6KA3AURKADAPK3JAK2
SCHEMBL28985646 0.62 PAX8 (0.40) MAPK8MAPK1MAP4K4ALDH1A1CYP1A2
SCHEMBL4888172 0.62 KDM4E (0.47) NTRK1IGF1RFGFR1NTRK2PIM1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250304571-A1 BIOLOGICALLY ACTIVE COMPOUNDS AND METHODS THEREOF SUZHOU KEEN THERAPEUTICS CO., LTD. (CN) 2025-10-02 US disclosed
EP-4565588-A1 BIOLOGICALLY ACTIVE COMPOUNDS AND METHODS THEREOF Suzhou Keen Therapeutics Co., Ltd. (CN) 2025-06-11 EP disclosed
WO-2023241620-A1 BIOLOGICALLY ACTIVE COMPOUNDS AND METHODS THEREOF SUZHOU KEEN THERAPEUTICS CO., LTD. (CN) 2023-12-21 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250304571-A1 BIOLOGICALLY ACTIVE COMPOUNDS AND METHODS THEREOF VHL, BRCA1, TERT PTK2 2231/4885RPS6KA3 3757/4885AURKA 2457/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.